A Comparison of Chitosan, Mesoporous Silica and Poly(lactic-co-glycolic) Acid Nanocarriers for Optimising Intestinal Uptake of Oral Protein Therapeutics

Files

9916456709501831_.pdf (952.87 KB)
  (Published version)

Date

2021

Authors

Wright, L.
Joyce, P.
Barnes, T.J.
Lundmark, R.
Bergström, C.A.S.
Hubert, M.
Prestidge, C.A.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Journal of Pharmaceutical Sciences, 2021; 110(1):217-227

Statement of Responsibility

Conference Name

Abstract

Efficacious oral delivery of therapeutic proteins remains challenging and nanoparticulate approaches are gaining interest for enhancing their permeability. In this study, we explore the ability for three comparably sized nanocarriers, with diverse physicochemical properties [i.e., chitosan (CSNP), mesoporous silica nanoparticles (MSNP) and poly(lactic-co-glycolic) acid (PLGA-NP)], to successfully facilitate epithelial uptake of a model protein, ovalbumin (OVA). We report the effect of nanoparticle surface chemistry and nanostructure on protein release, cell toxicity and the uptake mechanism in a Madin Darby Canine Kidney (MDCK) cell model of the intestinal epithelium. All nanocarriers exhibited bi-phasic OVA release kinetics with sustained and incomplete release after 4 days, and more pronounced release from MSNP than either polymeric nanocarriers. CSNP and MSNP displayed the highest cellular uptake, however CSNP was prone to significant dose-dependent toxicity attributed to the cationic surface charge. Approximately 25% of MSNP uptake was governed by a clathrin-independent endocytic mechanism, while CSNP and PLGA-NP uptake was not controlled via any endocytic mechanisms investigated herein. Furthermore, endosomal localisation was observed for CSNP and MSNP, but not for PLGA-NP. These findings may assist in the optimal choice and engineering of nanocarriers for specific intestinal permeation enhancement for oral protein delivery.

School/Discipline

Dissertation Note

Provenance

Description

Data source: Supplementary Data, https://doi.org/10.1016/j.xphs.2020.09.026

Access Status

Rights

Copyright 2020 American Pharmacists Association. Published by Elsevier Inc. Access Condition Notes: Accepted manuscript available after 1 October 2022

License

Call number

Persistent link to this record